Clinical Trials Browser

Phase 2 × Lenalidomide × Head & Neck × Clear all

NCT00287287 2020-06-12

REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas

Phase 2 Completed

25 enrolled 9 charts

Thyroid Neoplasms